Research Article | Open Access
Volume 2025 - 3 | Article ID 263 | http://dx.doi.org/10.51521/JJGASTRO-E401
Academic Editor: John Bose
Xia Chen1, Qiang Xiao1*
1Department of
Pediatrics, Affiliated Hospital of Chengdu University, Chengdu University,
Chengdu, Sichuan 610081, China.
*Correspondence: Qiang Xiao, Department of Pediatrics, Affiliated Hospital of
Chengdu University, Chengdu University, No.82, North 2 Section, Erhuan Road,
Chengdu City, Sichuan 610081, China
Citation: Xia
Chen, Qiang Xiao* (2025) EpOME Regulates Staphylococcus Aureus-Induced Allergic
Airway Inflammation by Targeting the NF-κB and MAPK Signaling Pathways.
IntJ Gastroenterol Hepatol Endosc. 2025 January;1-5.
Copyrights © 2025, Xia Chen, Qiang Xiao. This article is licensed under the
Creative Commons Attribution-Non Commercial-4.0-International-License-(CCBY-NC)
(bostonsciencepublishing.us). Usage and distribution for commercial purposes
require written permission.
Abstract
Allergic airway inflammation (AAI) is a
chronic disease caused by immune system dysfunction, leading to serious quality
of life impairments such as allergic rhinitis and asthma, especially in
children and newborns. Staphylococcus aureus is a common pathogen that plays a
crucial role in exacerbating these inflammatory conditions by activating key
immune pathways, including NF - κ B and MAPK. This study investigated the
potential therapeutic effect of linoleic acid metabolite 9,10-epoxyoctadecenoic
acid (EpoME) in regulating allergic airway inflammation induced by
Staphylococcus aureus. There are studies suggesting that EpoME may regulate
these inflammatory pathways to reduce inflammation, improve airway
hyperresponsiveness, and repair epithelial cell damage. In in vivo experiments,
we observed that EpoME treatment significantly reduced airway resistance and
improved lung compliance in a mouse model, indicating an improvement in airway
hyperresponsiveness. In addition, EpoME treatment reduced the levels of
pro-inflammatory cytokines such as IL-6, TNF - α, and IL-1 β in serum,
highlighting its role in reducing systemic and local inflammation. Western blot
analysis confirmed that EpoME inhibits the activation of NF - κ B and MAPK
signaling pathways, further supporting its anti-inflammatory effects. These
results suggest that EpoME may become a potential therapeutic agent for
treating allergic airway inflammation induced by Staphylococcus aureus by
targeting these key inflammatory pathways. This study emphasizes the
therapeutic potential of EpoME as an anti-inflammatory agent, particularly in
cases involving Staphylococcus aureus induced airway inflammation. EpoME may
provide a new approach for managing allergic airway diseases, which has great
significance for newborns and other susceptible populations.
Keywords
Allergic Airway Inflammation (AAI), 9,10-Epoxyoctadecenoic acid (EpOME),
Staphylococcus aureus, NF-κB signaling, MAPK signaling.
.png)
.jpg)
.gif)
.jpg)
